synthetic biologyGraveyard archive2013–2022

Zymergen

Zymergen was the SoftBank-backed poster child for machine-learning biomanufacturing, and it imploded barely four months after one of 2021's splashiest synthetic-biology IPOs. Founded in Emeryville in 2013 by Josh Hoffman, Zach Serber and Jed Dean — three ex-Amyris colleagues — it promised to engineer microbes the way software engineers write code, using automation, genomics and data science to make bio-based materials that beat petrochemicals. More than $875 million in venture capital poured in, led by SoftBank's Vision Fund, and in April 2021 Zymergen went public on Nasdaq at roughly a $3 billion valuation, raising about $530 million.

Years active

2013–2022

Peak valuation

$4.8B

Total raised

$1.4B

Peak headcount

~900

Biology as software

Zymergen was founded in 2013 in Emeryville, California by Josh Hoffman, Zach Serber and Jed Dean, three colleagues who had met at the pioneering synthetic-biology company Amyris. Their pitch was that microbial engineering, historically slow artisanal lab work, could be industrialized: pair high-throughput robotics with genomics, machine learning and data science to search vast genetic design spaces and 'biofacture' materials and chemicals that outperform petroleum-derived incumbents. Hoffman, a former McKinsey consultant, was the commercial and fundraising engine; Serber, a biophysicist, ran the science as chief science officer; Dean built the automation. It was a seductive thesis at exactly the moment capital was hunting for the next platform, and Zymergen positioned itself not as a drug company but as a horizontal engine that could make anything biology could make.

The SoftBank rocket

The money arrived fast and large. DCVC seeded and led a $44 million Series A in 2015; SoftBank led a $130 million Series B in 2016; and in December 2018 the SoftBank Vision Fund poured more than $400 million into a Series C that valued Zymergen near $1 billion, up from roughly $340 million months earlier. A $300 million Series D led by Baillie Gifford followed in July 2020. All told, Zymergen raised more than $875 million privately — Forbes later characterized the pre-IPO haul as north of $1 billion — making it one of the best-capitalized synthetic-biology companies in the world. What it did not have, underneath the platform narrative, was a scaled product actually generating revenue: 2020 product revenue rounded to roughly $13 million against annual cash burn well above $200 million.

Sign in

synthetic biologyGraveyard archive2013–2022

Zymergen

Zymergen was the SoftBank-backed poster child for machine-learning biomanufacturing, and it imploded barely four months after one of 2021's splashiest synthetic-biology IPOs. Founded in Emeryville in 2013 by Josh Hoffman, Zach Serber and Jed Dean — three ex-Amyris colleagues — it promised to engineer microbes the way software engineers write code, using automation, genomics and data science to make bio-based materials that beat petrochemicals. More than $875 million in venture capital poured in, led by SoftBank's Vision Fund, and in April 2021 Zymergen went public on Nasdaq at roughly a $3 billion valuation, raising about $530 million.

Years active

2013–2022

Peak valuation

$4.8B

Total raised

$1.4B

Peak headcount

~900

Biology as software

Zymergen was founded in 2013 in Emeryville, California by Josh Hoffman, Zach Serber and Jed Dean, three colleagues who had met at the pioneering synthetic-biology company Amyris. Their pitch was that microbial engineering, historically slow artisanal lab work, could be industrialized: pair high-throughput robotics with genomics, machine learning and data science to search vast genetic design spaces and 'biofacture' materials and chemicals that outperform petroleum-derived incumbents. Hoffman, a former McKinsey consultant, was the commercial and fundraising engine; Serber, a biophysicist, ran the science as chief science officer; Dean built the automation. It was a seductive thesis at exactly the moment capital was hunting for the next platform, and Zymergen positioned itself not as a drug company but as a horizontal engine that could make anything biology could make.

The SoftBank rocket

The money arrived fast and large. DCVC seeded and led a $44 million Series A in 2015; SoftBank led a $130 million Series B in 2016; and in December 2018 the SoftBank Vision Fund poured more than $400 million into a Series C that valued Zymergen near $1 billion, up from roughly $340 million months earlier. A $300 million Series D led by Baillie Gifford followed in July 2020. All told, Zymergen raised more than $875 million privately — Forbes later characterized the pre-IPO haul as north of $1 billion — making it one of the best-capitalized synthetic-biology companies in the world. What it did not have, underneath the platform narrative, was a scaled product actually generating revenue: 2020 product revenue rounded to roughly $13 million against annual cash burn well above $200 million.

The $3 billion IPO

On April 22, 2021, Zymergen began trading on the Nasdaq Global Select Market under the ticker ZY, in an upsized IPO underwritten by J.P. Morgan and Goldman Sachs. Shares priced at $31, raising about $530 million and valuing the company near $3 billion; the stock ran higher still, pushing peak market capitalization toward $4.8 billion. The centerpiece of the story was Hyaline, an optically clear, flexible polyimide film aimed at foldable phones, touch sensors and other electronics, which Zymergen claimed addressed a $1 billion market. For a few months, Zymergen was the marquee example of synthetic biology graduating from science project to public company — the proof that a bio-based materials platform could command Silicon Valley multiples.

August 3, 2021: no revenue

It lasted about a hundred days. After the market closed on August 3, 2021, Zymergen disclosed that key customers had run into technical problems integrating Hyaline into their own manufacturing, that the company now expected no product revenue in 2021, and that any 2022 product revenue would be 'immaterial.' The stock collapsed roughly 69% in after-hours trading, erasing about $2.5 billion in market value, and fell around 76% at its worst. Josh Hoffman was removed as CEO the same day, replaced by chairman and former Illumina chief Jay Flatley as acting CEO. The single product on which the entire commercial story rested had no path to near-term revenue, and the market repriced the platform accordingly — from a multibillion-dollar future to a distressed asset almost overnight.

Absorbed by Ginkgo

There was no recovery. Layoffs followed within weeks, a securities class action was filed, and with product revenue gone Zymergen's real value was its automated strain-engineering foundry — the one asset a rival wanted. On July 25, 2022, Ginkgo Bioworks agreed to acquire Zymergen in an all-stock deal valuing it at about $300 million, a roughly 90% markdown from the IPO price barely fifteen months earlier. The deal closed October 19, 2022, folding Zymergen's platform and remaining staff into Ginkgo's cell-programming operation. Two years later, on September 13, 2024, the SEC charged Zymergen with misleading IPO investors through 'unsupported hype' about Hyaline's market and sales prospects; the company agreed to a $30 million penalty without admitting or denying the findings. Zymergen was proof of the era's central synthetic-biology hazard: a brilliant platform, a spectacular fundraise, and no commercial product to hold any of it up.

What worked, what broke

What worked

Built one of the industry's most advanced automated, machine-learning-driven strain-engineering foundries — the asset Ginkgo Bioworks ultimately acquired the company to obtain.
Raised more than $875 million in private capital and drew marquee backers including the SoftBank Vision Fund, DCVC and Baillie Gifford.
Completed one of 2021's highest-profile synthetic-biology IPOs, pricing at $31 a share to raise about $530 million at a roughly $3 billion valuation.
Advanced Hyaline, an optically clear flexible polyimide film for foldable displays and electronics, from lab concept toward a claimed billion-dollar market opportunity.
Popularized the 'biology as software' thesis — automation plus genomics plus machine learning — that shaped how a generation of synthetic-biology platforms pitched investors.

What broke

A yawning commercialization gap: a powerful R&D platform generating only about $13 million of product revenue in 2020 against annual cash burn well over $200 million.
Total dependence on a single flagship product, Hyaline, which hit customer manufacturing-integration problems and generated no near-term revenue — collapsing the entire commercial story in one disclosure.
Overhyped market claims: the SEC later found the $1 billion Hyaline market rested on flawed assumptions and 'unsupported hype,' resulting in a $30 million penalty.
A hype-cycle IPO priced on projections rather than product traction, which unwound within four months of going public and destroyed roughly 90% of the company's value.
Leadership rupture at the worst moment — CEO and co-founder Josh Hoffman was removed the day the bad news broke, leaving the company rudderless as the stock collapsed.

Sources

Obituary authored Jul 2, 2026 via Sonnet 4.5 + web_search.

What’s new

Join affiliate network